lung
major
entri
point
mani
detriment
pathogen
human
health
onslaught
pathogen
encount
lung
counteract
protect
immun
respons
gener
local
stimul
vaccin
strategi
prevent
pathogen
infect
discuss
use
viruslik
particl
vlp
nonpathogen
deriv
virus
protein
cage
structur
construct
new
vaccin
exploit
lung
site
immunostimul
vlp
uniqu
abil
engin
near
molecular
level
detail
knowledg
composit
structur
summari
research
develop
vlpbase
vaccin
lung
present
suggest
promis
result
futur
vaccin
develop
nanoparticl
present
ideal
size
scaffold
attach
present
antigen
immun
system
induc
respons
multival
present
also
taken
cell
mani
synthet
platform
util
polymer
nanoparticl
dendrim
membran
structur
ie
liposom
polymerosom
micel
review
focu
util
protein
cage
andor
viruslik
particl
vlp
class
nanoscaffold
great
demonstr
potenti
sever
good
review
written
topic
util
vlp
develop
vaccin
immunogen
nanomateri
review
want
provid
greater
discuss
make
vlp
uniqu
materi
point
view
addit
focu
util
vlp
target
protect
immun
vlp
selfassembl
protein
architectur
devoid
accessori
protein
nucleic
acid
hollow
interior
surround
multisubunit
protein
coat
addit
classic
vlp
form
welldefin
regular
structur
anoth
class
vlp
compos
ensembl
biomolecul
less
regular
structur
also
exist
particl
focu
discuss
note
case
influenza
background
vlp
studi
combat
signific
pathogen
human
health
strict
sens
vlp
deriv
viral
compon
nonvir
protein
cage
structur
exist
resembl
properti
similar
vlp
simplic
refer
nonvir
protein
cage
vlp
like
throughout
review
predominantli
use
vlp
monik
discuss
design
manipul
immun
respons
although
principl
discuss
appli
class
vlp
nonpathogen
replic
defici
viral
genom
protein
cofactor
import
infect
remov
make
ideal
suit
construct
new
vaccin
risk
virul
occur
attenu
viral
strain
addit
produc
high
quantiti
heterolog
recombin
gene
express
varieti
express
system
includ
escherichia
coli
yeast
baculoviru
mammalian
cell
vlp
due
multicompon
structur
thu
larg
molecular
weight
particularli
simpl
purifi
mani
case
make
product
larg
scale
econom
viabl
extens
research
field
virolog
protein
biochemistri
structur
function
relationship
underpin
vast
array
virus
protein
cage
exploit
util
modifi
vlp
counterpart
structur
inform
particular
signific
sinc
allow
predict
larg
degre
certainti
close
molecular
level
atom
amino
acid
side
chain
locat
within
larg
macromolecular
vlp
structur
allow
research
introduc
chang
molecular
architectur
level
knowledg
confid
chang
might
modifi
structur
exploit
use
siteselect
mutagenesi
incorpor
new
amino
acid
reactiv
uniqu
properti
exampl
mutat
introduc
cystein
residu
interior
exterior
cage
allow
rang
nonn
molecul
adjuv
target
moieti
coval
select
attach
surfac
choic
synthet
modif
straight
forward
guarante
quantit
label
genet
manipul
insert
peptid
protein
guarante
exact
placement
control
stoichiometri
ad
compon
figur
genet
manipul
system
includ
insert
peptid
sequenc
within
flexibl
loop
exterior
addit
peptid
protein
onto
expos
termini
vlp
coat
protein
addit
adapt
protein
associ
capsid
wall
either
interior
exterior
genet
modifi
incorpor
larg
cargo
either
exterior
interior
vlp
abil
util
chemic
genet
approach
modifi
vlp
welldefin
homogen
composit
structur
unmatch
nano
system
typic
employ
similar
purpos
furthermor
thousand
protein
cage
virus
character
varieti
size
physic
properti
provid
librari
potenti
architectur
develop
design
antigen
nanoparticl
research
field
begun
scratch
surfac
abil
manipul
vlp
multival
display
antigen
immunostimulatori
agent
achiev
thu
far
discuss
provid
excit
possibl
futur
infect
initi
mucos
surfac
respiratori
gi
reproduct
tract
respiratori
infect
common
occurr
individu
age
immun
statu
thu
repres
signific
global
health
concern
despit
signific
effort
field
vaccin
develop
vaccin
still
lack
mani
clinic
relev
lower
respiratori
tract
pathogen
vlp
known
induc
potent
mucos
immun
respons
presum
resembl
virus
shown
induc
innat
adapt
immun
respons
studi
shown
order
vlp
induc
potent
antibodi
respons
must
reach
lower
part
lung
suggest
import
mucosa
lung
interact
vlp
immun
system
lung
structur
function
relationship
although
resist
pose
physic
barrier
prevent
vast
major
infect
success
pathogen
enter
bodi
via
either
direct
infect
mucos
epithelium
penetr
mucos
surfac
unlik
mucos
site
within
bodi
protect
immunolog
shape
commens
flora
lung
long
consid
steril
recent
research
entertain
idea
commens
commun
lung
howev
network
commens
microorgan
lung
significantli
underrepres
compar
mucos
site
reason
lung
reli
intric
network
immun
cell
antimicrobi
secret
defens
close
relationship
structur
extens
vasculatur
function
ga
exchang
lung
make
organ
especi
vulner
inflamm
howev
uniqu
anatomi
lung
ensur
exposur
million
extern
antigen
daili
basi
thu
although
execut
rapid
effect
respons
pathogen
desir
lung
protect
delic
lung
tissu
inflammationinduc
damag
essenti
proper
function
vital
organ
ensur
rapid
immun
respons
simultan
protect
lung
tissu
local
respons
induc
potent
minim
damag
one
exampl
induct
effici
yet
nondamag
local
immun
respons
format
bronchusassoci
lymphoid
tissu
balt
although
constitut
present
mammalian
speci
perman
balt
present
mice
human
howev
format
induc
balt
ibalt
occur
mice
human
respons
certain
viral
bacteri
infect
well
steril
inflamm
ibalt
format
describ
respons
influenza
infect
mice
report
suffici
immunemedi
resolut
influenza
infect
mice
lack
peripher
lymphoid
organ
possess
ibalt
clear
viru
infect
also
surviv
higher
dose
viru
challeng
normal
mice
result
support
protect
role
ibalt
variou
viral
bacteri
infect
suggest
respons
gener
ibalt
potenti
less
damag
lung
tissu
system
immun
respons
intranas
inocul
mice
small
heat
shock
protein
shsp
nanoparticl
larg
due
format
ibalt
protect
mice
lethal
challeng
variou
influenza
virus
pneumoviru
even
coronaviru
respons
sever
acut
respiratori
syndrom
sarscov
moreov
shsp
inocul
significantli
reduc
morbid
associ
coxiella
brunetii
infect
contrast
salineinocul
mice
shspinocul
mice
retain
preinfect
bodyweight
despit
similar
lung
bacteri
burden
suggest
shspinduc
local
immun
respons
lung
less
damag
system
immun
respons
similar
level
protect
achiev
intranas
inocul
mice
nanoparticl
deriv
archaeon
methanocaldococcu
jamannashi
shsp
bacteriophag
vlp
carri
resembl
subsequ
challeng
agent
indic
vlpinduc
protect
antigennonspecif
ibalt
develop
adjac
larg
airway
known
contain
b
cell
follicular
dendrit
cell
fdc
germin
center
gc
mice
lack
adapt
cell
shown
incap
develop
ibalt
respons
vlp
inocul
ibaltmedi
protect
induc
variou
vlp
critic
depend
presenc
adapt
immun
cell
also
presenc
preform
ibalt
mous
lung
prior
challeng
significantli
reduc
inflammationinduc
tissu
damag
otherwis
associ
infectioninduc
ibalt
mice
preform
ibalt
time
influenza
challeng
increas
accumul
alveolar
macrophag
am
dc
ibalt
area
also
tracheobronchi
lymph
node
tbln
translat
acceler
kinet
intensifi
influenzaspecif
cell
respons
mice
extens
toxicolog
studi
shown
advers
effect
associ
multipl
administr
vlp
moreov
format
ibalt
either
respons
vlp
treatment
infect
mice
opportunist
fungu
pneumocysti
murina
induc
type
immun
imprint
thu
target
induct
ibalt
vlpbase
vaccin
would
induc
state
immun
readi
subsequ
assault
could
potenti
provid
broad
rang
protect
varieti
pathogen
major
virus
particl
nm
posit
size
small
poorli
immunogen
solubl
particl
includ
protein
small
protein
complex
often
present
extracellular
space
nm
bacteria
much
bigger
fall
size
rang
nm
size
particul
natur
virus
commonli
thought
respons
abil
directli
cross
wall
lymphat
vessel
lymphat
system
thought
reach
b
cell
follicl
lymph
node
surfac
dc
macrophag
b
cell
highli
repetit
protein
subunit
structur
viral
capsid
make
wellequip
induct
humor
immun
due
effici
bcell
receptor
bcr
crosslink
induct
neutral
antibodi
abil
induc
humor
immun
advantag
antivir
vaccin
format
pathogenspecif
antibodi
either
directli
prevent
case
induct
neutral
antibodi
significantli
acceler
nonneutr
antibodi
viru
clearanc
link
et
al
demonstr
import
repetit
structur
viral
capsid
induct
effici
adapt
immun
respons
eleg
studi
report
repetit
structur
viral
capsid
requir
bind
natur
antigen
nonspecif
igm
antibodi
fix
complement
complex
effici
activ
b
cell
gc
respons
system
administr
bacteriophagederiv
vlp
solubl
naiv
mice
result
effici
vlp
bind
noncogn
b
cell
via
complement
igm
vlp
subsequ
transport
fdc
process
thought
requir
activ
clonal
expans
b
cell
within
gc
effici
transport
independ
prior
immun
correl
stronger
induct
gc
respons
inhibit
presenc
igg
antibodi
turn
requir
effici
induct
fdc
respons
anoth
studi
bessa
et
al
demonstr
import
b
cell
lowaffin
transport
vlp
lung
mucosa
spleen
induct
antibodi
respons
induct
antibodi
respons
occur
within
bcell
follicl
secondari
lymphoid
organ
rather
mucosa
vlp
administ
intranas
bound
bcr
lung
b
cell
engag
bcr
addit
format
local
gc
induct
vlpspecif
iga
antibodi
result
transport
bcrbound
vlp
splenic
b
cell
follicl
induct
effici
system
igg
respons
also
shown
transport
vlp
b
cell
independ
fc
receptor
complement
receptor
limit
lowaffin
bcr
although
vast
major
vaccin
current
administ
system
earlier
studi
bessa
et
al
demonstr
differ
efficaci
system
igg
iga
respons
follow
subcutan
versu
intranas
immun
contrast
system
immun
howev
intranas
immun
elicit
local
product
iga
result
laboratori
shown
intranas
deliveri
ovalbumin
ova
chemic
conjug
shsp
deriv
methanocaldococcu
jannaschii
hyperthermophil
archaeon
naiv
mice
significantli
acceler
intensifi
ovaspecif
antibodi
respons
compar
mice
inocul
ova
alon
shsp
alon
ova
shsp
admixtur
unconjug
ova
shsp
mix
togeth
prior
inocul
mice
case
shsp
engin
util
crystallograph
structur
inform
incorpor
reactiv
cystein
genet
via
sitedirect
mutagenesi
shsp
gene
allow
coval
attach
extern
display
model
ova
antigen
conjug
ova
achiev
util
heterobifunct
crosslink
reagent
react
select
cystein
thiol
shsp
protein
lysin
residu
ova
cystein
residu
placement
well
linker
length
within
heterobifunct
crosslink
screen
gain
construct
allow
optim
crosslink
ovalbumin
cage
result
optim
shspova
construct
show
conjug
yield
rapid
product
antibodi
ovalbumin
regard
ova
alon
unconjug
inocul
strong
antibodi
respons
observ
day
postchalleng
howev
conjug
shspova
yield
optimum
igg
ova
within
day
singl
dose
inocul
addit
peak
ovaspecif
igg
titer
occur
least
day
sooner
day
postchalleng
pretreat
mice
differ
vlp
deriv
bacteriophag
enhanc
immunogen
achiev
coval
attach
ova
shsp
attribut
carrier
effect
immunogen
observ
inject
ova
alon
vlp
alon
admixtur
attribut
adjuv
effect
vlp
moreov
pretreat
enhanc
product
mucos
iga
well
isotypeswitch
ovaspecif
serum
igg
result
speak
power
util
vlp
abil
manipul
structur
chemic
allow
broad
rang
antigen
immunostimulatori
molecul
construct
design
antigen
particl
direct
immun
respons
despit
signific
worldwid
effort
design
crossprotect
influenza
vaccin
influenza
viru
one
lead
caus
respiratori
distress
morbid
even
mortal
worldwid
accord
season
influenza
epidem
result
million
case
sever
ill
lethal
case
per
year
potenti
vaccin
target
respiratori
mucosa
acknowledg
us
fdaapprov
intranas
deliv
flumist
vaccin
shown
effect
provid
comprehens
local
immun
inject
annual
influenza
vaccin
importantli
immun
induc
flumist
inject
counterpart
shown
provid
protect
secondari
bacteri
challeng
mice
streptococcu
pneumonia
one
lead
caus
secondari
postinfluenza
bacteri
infect
thu
environ
respiratori
mucosa
make
desir
locat
vaccin
deliveri
annual
influenza
outbreak
difficult
control
exist
vaccin
formul
induc
neutral
antibodi
respons
specif
subtyp
hemagglutinin
ha
neuraminidas
na
protein
viru
capsid
exterior
suscept
amino
acid
mutat
antigen
site
known
antigen
drift
addit
problem
associ
current
state
influenza
vaccin
develop
emerg
number
avianderiv
influenza
virus
estim
wild
bird
sourc
influenza
ha
subtyp
human
immun
system
naiv
genet
reassort
rna
avian
human
influenza
mutat
enabl
viru
becom
transmiss
among
human
popul
given
high
virul
avian
sourc
influenza
may
lead
global
pandem
avian
influenza
strain
highli
pathogen
domest
poultri
current
fda
approach
influenza
vaccin
product
ie
rais
chicken
egg
may
viabl
option
overcom
limit
number
nonegg
rais
vlpbase
influenza
vaccin
platform
engin
test
mice
ferret
major
area
interest
field
vaccin
develop
lungassoci
pathogen
like
influenza
new
vaccin
strategi
provid
broad
serotyp
protect
current
fdaapprov
formul
yearli
influenza
vaccin
trival
composit
two
strain
one
b
strain
determin
preval
given
year
howev
due
antigen
drift
shift
vaccin
often
leav
individu
suscept
infect
new
emerg
strain
influenza
target
vaccin
formul
case
formul
product
supplementari
vaccin
chicken
egg
costli
slow
may
ineffect
emerg
influenza
strain
avian
origin
altern
vlp
provid
platform
rapid
product
could
use
produc
vaccin
candid
rapidli
emerg
strain
addit
highli
conserv
antigen
influenza
could
util
construct
vlp
provid
broad
serotyp
protect
although
influenza
vlp
form
regular
structur
ensembl
influenza
protein
discuss
warrant
provid
complet
pictur
strategi
taken
limit
observ
combat
import
pathogen
human
health
implement
altern
tradit
influenzavaccin
design
structur
protein
influenza
viru
produc
mammalian
cell
line
assembl
vlp
particl
releas
cell
cultur
media
much
like
viru
bud
approach
result
incorpor
viru
glycoprotein
surfac
vlp
thu
influenza
vlp
resembl
actual
influenza
morpholog
number
influenza
vlp
gener
mammalian
cell
line
insect
cell
use
baculoviru
express
system
describ
detail
anim
intranas
vaccin
vlp
contain
either
ha
matrix
protein
influenza
protect
lethal
infect
close
relat
influenza
protect
base
induct
haspecif
neutral
antibodi
equal
protect
subleth
vaccin
correspond
live
viru
quan
et
al
attempt
provid
protect
heterolog
influenza
infect
immun
mice
influenza
vlp
contain
ha
protein
vlp
although
improv
surviv
observ
heterolog
influenza
challeng
vlp
incompar
protect
homolog
challeng
much
like
influenzabas
vlp
significantli
capabl
induc
strong
antibodi
respons
recombin
ha
rha
alon
despit
reason
success
vlpbase
influenza
vaccin
mostli
protect
parent
close
relat
parent
strain
provid
broad
serotyp
protect
desir
overcom
strain
specif
improv
overal
immunogen
influenza
vlpbase
vaccin
immun
adjuv
incorpor
vlp
formul
instanc
inclus
flagellin
agonist
improv
immunogen
influenza
vlp
heterosubtyp
challeng
safe
altern
suit
largescal
product
plantbas
express
system
util
product
vlpbase
intramuscular
vaccin
protect
ld
challeng
influenza
mice
howev
limit
protect
mostli
homolog
close
relat
heterolog
strain
influenza
achiev
use
vlpbase
system
note
previou
section
vlp
deriv
influenza
obtain
shown
achiev
broad
crossprotect
heterolog
influenza
strain
altern
noninfluenza
vlp
util
molecular
scaffold
display
antigen
peptid
protein
influenza
stimul
protect
immun
respons
approach
allow
research
produc
vlp
carri
addit
influenza
antigen
obtain
simpl
heterolog
protein
express
produc
rel
high
yield
section
highlight
strategi
exploit
use
noninfluenza
vlp
scaffold
construct
influenza
specif
vaccin
highlight
uniqu
featur
util
vlp
vaccin
mention
ha
na
protein
target
mani
influenza
vaccin
strategi
subject
antigen
drift
altern
transmembran
protein
influenza
viru
explor
potenti
candid
influenza
vaccin
although
minor
protein
express
influenza
viru
form
protonselect
ion
channel
thu
essenti
product
viral
infect
contrast
ha
na
protein
highli
conserv
across
influenza
speci
subject
antigen
drift
shift
furthermor
antibodi
shown
protect
influenza
infect
mice
logic
consequ
vlpbase
vaccin
target
engin
multipl
group
test
protect
influenza
challeng
util
hepat
b
viru
core
protein
hbc
vlp
scaffold
neirynck
et
al
construct
genet
fusion
ie
splice
togeth
two
gene
yield
fuse
polyprotein
upon
express
extracellular
domain
hbc
test
vivo
protect
mice
lethal
challeng
influenza
via
induct
neutral
antibodi
similar
level
protect
gener
via
either
intranas
mucos
intraperiton
system
administr
vlp
howev
multipl
administr
vlp
requir
protect
last
week
postimmun
anoth
vlpbase
vaccin
influenza
engin
chemic
coupl
immunodomin
region
bacteriophag
induc
protect
influenza
challeng
mediat
antibodydepend
cellmedi
cytotox
antibodi
induc
amelior
diseas
caus
low
high
challeng
dose
influenza
viru
due
natur
antibodydepend
cellmedi
cytotox
respons
prevent
influenza
infect
make
insuffici
yearli
epidem
full
protect
desir
genet
fusion
univers
epitop
papaya
mosaic
viru
papmv
vlp
led
product
antibodi
coadminist
alum
provid
nearli
complet
protect
lethal
challeng
mice
influenza
interestingli
immunogen
papmv
vaccin
platform
critic
depend
multimer
coat
protein
monomer
papmv
fuse
hepat
c
viru
epitop
insuffici
induct
immun
respons
either
platform
fuse
epitop
anoth
studi
group
papmv
vlp
use
adjuv
improv
efficaci
trival
human
inactiv
influenza
tiv
vaccin
administ
system
papmv
vlp
enhanc
immun
respons
coadminist
tiv
provid
protect
challeng
heterosubtyp
influenza
viru
protect
lethal
influenza
challeng
mice
gener
intranas
administr
vlp
show
biochem
resembl
influenza
viru
also
contain
influenza
epitop
mice
inocul
either
shsp
vlp
shown
significantli
resist
influenza
challeng
compar
salineinocul
mice
vlpprotect
mice
reduc
lung
viral
titer
lose
bodi
weight
improv
surviv
rate
somewhat
unconvent
approach
antigen
display
describ
util
vlp
bacteriophag
interior
space
capsid
util
placement
influenza
antigen
case
wellcharacter
selfassembl
exploit
coordin
scaffold
protein
sp
direct
assembl
cp
vlp
repres
triangul
number
describ
viru
structur
biomimet
strategi
conserv
nucleoprotein
np
incorpor
interior
produc
vlp
np
display
would
influenza
interior
incorpor
np
achiev
creat
fusion
protein
np
scaffold
protein
sp
direct
assembl
coat
protein
result
incorpor
npsp
interior
vlp
approach
show
particl
contain
high
intern
concentr
either
npsp
fusion
truncat
np
variant
easili
engin
yield
homogen
vlp
contain
np
rapidli
purifi
step
vlp
provid
exquisit
protect
high
dose
ld
multipl
serotyp
influenza
addit
protect
found
tcell
depend
aid
clearanc
infect
cell
express
nonexpos
intern
influenza
peptid
influenza
np
interestingli
also
observ
antibodi
respons
found
full
length
np
encapsul
observ
truncat
variant
np
show
tcelldepend
level
protect
result
suggest
engin
vlp
control
antigen
display
either
antibodyor
tcellmedi
respons
target
use
vlp
deriv
flockhous
viru
fhv
research
incorpor
peptid
flexibl
loop
region
vlp
deriv
conserv
stalk
portion
ha
compos
major
bind
surfac
broadli
protect
antibodi
hypothes
display
smaller
conserv
fragment
vlp
platform
broadli
protect
antibodi
fragment
ha
stalk
could
gener
produc
broad
serotyp
protect
respons
design
incorpor
helixturnhelix
peptid
contain
part
conserv
peptid
provid
major
bind
surfac
neutral
antibodi
predict
helixturnhelix
peptid
motif
would
retain
helic
structur
peptid
epitop
provid
nativ
structur
peptid
found
full
length
ha
insert
flexibl
loop
region
expos
surfac
fhv
promis
strategi
base
protein
structur
particl
fhv
contain
prescrib
peptid
fragment
unabl
elicit
neutral
antibodi
respons
cryoem
reconstruct
reveal
two
differ
construct
made
construct
lack
desir
helic
peptid
structur
yield
best
protect
comparison
construct
found
maintain
helixturnhelix
motif
maintain
structur
context
found
peptid
within
full
length
ha
lack
protect
immun
respons
wellfold
helixturnhelix
construct
suggest
result
steric
hinder
orient
peptid
fragment
display
within
loop
fhv
reengin
particl
allow
better
exposur
peptid
may
provid
intend
immun
respons
strategi
still
provid
use
start
point
futur
work
area
vaccin
develop
recent
nabel
cowork
construct
immunogen
nanoparticl
util
protein
cage
nanoparticl
ferritin
vlplike
platform
display
full
length
ha
structur
inform
ferritin
fn
indic
nterminu
fn
vlp
project
toward
exterior
cage
subunit
organ
threefold
arrang
spatial
complement
trimer
ha
stalk
cterminu
ha
use
structur
approach
fusion
protein
consist
full
length
ha
cterminu
fuse
nterminu
fn
subunit
construct
recombin
mammalian
cell
express
hafn
fusion
yield
appear
fulli
assembl
vlp
consist
protrud
vivo
studi
mice
ferret
show
hafn
vlp
produc
potent
immun
respons
broader
protect
current
licens
season
flu
vaccin
find
indic
potenti
power
vlp
engin
approach
highlight
uniqu
abil
combin
molecularstructur
inform
crystallographi
cryoelectron
microscopi
ration
design
bioengin
immunogen
nanoparticl
one
mechan
self
versu
nonself
recognit
mediat
pattern
recognit
receptor
prr
abundantli
express
dc
well
mucos
epithelium
prr
recogn
highli
conserv
structur
among
pathogen
term
pathogenassoci
molecular
pattern
pamp
distinguish
pattern
host
cellular
damag
call
dangerassoci
molecular
pattern
prr
stimul
pamp
gener
result
pathogeninduc
inflamm
associ
tissu
damag
dangerassoci
molecular
patterninduc
steril
inflamm
tend
much
less
damag
host
thu
recogn
abil
prime
immun
system
induct
nondamag
inflamm
could
benefici
develop
immunoprohylaxi
immunotherapeut
prr
target
mean
amplifi
focus
vlpinduc
immun
explor
multipl
group
bessa
et
al
demonstr
vlp
spontan
packag
bacteri
rna
selfassembl
process
thu
carri
ligand
effici
induc
mucos
system
immun
respons
group
recent
report
unlik
solubl
protein
antigen
case
dimer
vlp
presum
due
size
repetit
structur
effici
induc
fdc
phenomenon
directli
translat
effici
antigen
present
bcell
activ
author
present
compel
argument
effici
transport
vlp
bcell
follicl
correl
stronger
induct
gc
anoth
eleg
studi
group
demonstr
subset
dc
respons
present
vlp
context
cell
mhc
class
pathway
yet
present
vlp
util
mhc
class
ii
pathway
cell
possess
restrict
fact
perform
either
subset
dc
antigen
present
context
lung
predominantli
accomplish
either
alveolar
macrophag
am
dc
airway
dc
parenchym
dc
recent
shown
intranas
deliv
vlp
acceler
matur
traffick
antigen
present
cell
manner
interestingli
shown
similar
effect
lung
cell
elicit
infect
mice
opportunist
fungu
pneumocysti
murina
either
infect
pneumocysti
vlp
inoculationprotect
mice
challeng
lethal
dose
influenza
viru
therefor
nasal
instal
vlp
immunolog
imprint
lung
environ
make
reactiv
less
damag
context
subsequ
infect
intranas
inocul
mice
vlp
also
protect
pulmonari
challeng
bacteri
pathogen
mice
instil
five
dose
shsp
shown
protect
morbid
follow
coxiella
burnetii
challeng
although
nanoparticl
reduc
lung
bacteri
burden
coxiella
contrast
mocktreat
mice
nanoparticleprotect
mice
lose
bodyweight
result
coxiella
infect
recent
studi
demonstr
mice
treat
shsp
significantli
resist
lethal
pulmonari
challeng
methicillinresist
staphylococcu
aureu
interestingli
unlik
shspmediat
protect
influenza
viru
larg
due
innat
immun
respons
regard
scid
wt
mice
treat
shsp
equal
protect
methicillinresist
staphylococcu
aureu
pneumonia
suggest
import
role
innat
immun
system
specif
cell
neutrophil
shspmediat
protect
gram
posit
bacterium
result
confirm
recent
studi
demonstr
protect
pulmonari
challeng
either
influenza
viru
streptococcu
pneumonia
achiev
mice
inocul
papmv
vlp
also
agreement
result
stimul
innat
immun
signal
reduc
lung
tissu
damag
suggest
respons
protect
follow
papmv
vlp
inocul
thu
vlp
repres
uniqu
versatil
strategi
alter
immun
respons
lung
combin
vlpmediat
reduct
inflammationmedi
host
tissu
damag
make
ideal
candid
vaccin
platform
varieti
lung
pathogen
util
vlp
stimul
protect
immun
respons
well
report
commerci
vaccin
base
vlp
clinic
avail
howev
use
vlp
scaffold
manipul
engin
near
atom
level
precis
incorpor
antigen
immunostimul
molecul
choic
multival
display
provid
even
greater
prospect
advanc
vaccin
develop
highli
desir
design
engin
produc
particl
complet
genet
mean
allow
rapid
manufactur
complet
vlpantigen
complex
heterolog
express
rang
host
cell
vlp
platform
permit
display
immunogen
materi
insid
outsid
capsid
could
use
select
display
direct
immun
respons
base
spatial
arrang
antigen
addit
harbor
multipl
kind
immunostimul
target
moieti
vlp
platform
could
result
construct
contain
exampl
protein
antigen
adjuv
approach
would
allow
codisplay
within
context
nanoparticl
util
vlp
allow
modif
made
near
molecular
level
precis
easili
accomplish
nanoparticl
platform
addit
abil
vlp
gener
protect
immun
respons
lung
particularli
import
preval
potenti
futur
epidem
caus
respiratori
pathogen
target
particular
interest
includ
influenza
current
vaccin
strategi
fulli
protect
respiratori
pathogen
respiratori
syncyti
viru
rsv
vaccin
current
avail
could
also
target
vlp
technolog
potenti
overcom
limit
associ
classic
vaccin
design
viruslik
particl
vlp
self
assembl
protein
structur
often
contain
hollow
interior
vlp
produc
heterolog
differ
host
allow
rapid
gener
costeffect
product
biochem
structur
knowledg
virus
allow
manipul
vlp
near
atom
level
knowledg
chemic
andor
genet
approach
util
incorpor
antigen
immunostimul
moititi
onto
vlp
vlp
serv
platform
immunostimul
materi
develop
mucos
surfac
predomin
entri
point
pathogen
caus
sever
human
diseas
vlp
induc
potent
mucos
immun
respons
vlp
use
stimul
induc
bronchusassoci
lymphoid
tissu
provid
local
immun
protect
lung
induc
bronchusassoci
lymphoid
tissu
provid
rapid
immun
respons
pathogen
lung
vlp
size
repetit
structur
make
ideal
platform
induc
humor
immun
influenza
present
constant
threat
human
health
new
vaccin
strategi
need
provid
broad
protect
vlp
deriv
influenza
provid
limit
protect
suitabl
vaccin
develop
vlp
deriv
noninfluenza
viru
present
use
scaffold
influenza
vaccin
develop
molecular
engin
vlp
provid
great
promis
futur
develop
influenza
vaccin
repetit
structur
vlp
scaffold
exploit
induct
dendrit
cell
respons
pattern
recognit
receptor
vlpinduc
protect
bacteri
pneumonia
role
innat
immun
nanomedicin
lond
author
manuscript
avail
pmc
april
viruslik
particl
genet
modifi
incorpor
peptid
protein
antigen
genet
fusion
cntermini
top
scaffold
protein
adapt
associ
protein
capsid
middl
insert
peptid
sequenc
flexibl
loop
region
capsid
genet
modif
shown
schemat
modif
rectangl
repres
gene
segment
ensur
exact
placement
within
final
viruslik
particl
structur
provid
exact
knowledg
copi
found
within
particl
